<DOC>
	<DOCNO>NCT01122771</DOCNO>
	<brief_summary>This protocol evaluate efficacy safety various combination three drug ; AmBisome , Paromomycin Miltefosine reduce total dosage standard treatment total dose 15mg/kg AmBisome .</brief_summary>
	<brief_title>Phase III , Study Three Short Course Combo ( Ambisome® , Miltefosine , Paromomycin ) Compared With AmBisome Treatment VL Bangladesh</brief_title>
	<detailed_description>Visceral leishmaniasis ( VL ) severe form leishmaniasis . The causative parasite Bangladesh almost exclusively L. donovani . • The current treatment option Bangladesh satisfactory either toxic long , limited use woman childbearing age due possible teratogenicity , long treatment duration lead non-compliance possible emergence resistance expensive . In collaboration Indian Medical Research Council investigator India , DNDi initiate combination trial treatment VL Bihar , India 2008 include 624 patient age 5 - 60 . The combination use present study . An interim safety review conduct first 120 patient include Indian VL Combination study reveal safety issue combination treatment . The enrolment complete final result 624 patient expect Q1 2010 . This randomize , control , open-label , parallel group study compare safety efficacy different combination regimens AmBisome treatment VL Bangladesh . This trial design two step : Step 1 : First 120 patient recruited hospital set study include parasitology laboratory assessment Community Based Medical College , Bangladesh ( CBMC , B ) , primarily purpose reconfirm safety combination treatment Bangladesh . Pending review approval independent DSMB Day 45 data , step 2 commence . Step 2 : Approximately 554 Patients recruit treated Upazilla Health Centre 's ( UZHC ) , situate endemic region Bangladesh . We use rapid diagnostic test ( RDT ) limit laboratory assessment available centre . Female patient stratify accord marital status , unmarried woman child-bearing age stratify receive treatment contain Miltefosine , marry woman stratify receive one four treatment regimen must consent use approve method contraception undergo pregnancy test start study . Child-bearing age define achieve menarche . There one plan safety review assess safety initial cure Day 45 follow completion Step 1 .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Paromomycin</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>VL proven parasitological examination splenic bone marrow aspirate . Parasite burden grade accord Chulay Bryceson 1983 subsequently adopt WHO . ( Step 1 ) History fever , least 2 week one following criterion : Anaemia ( 5 &lt; Hb &lt; 10g/dl ) , Loss weight , Splenomegaly rk39 positive baseline assessment willing able attend followup visit Male Female age : 560 yr Written inform consent patient patient 's parent guardian patient 18 yr , addition write assent patient 11 17 yrs age . If patient parent/guardian illiterate impartial witness present consenting procedure also sign . Married woman childbearing potential ( defined woman achieve menarche ) use assure method contraception unwilling use assure method contraception duration treatment three month . Assured method contraception include i.e . IUCD depot hormone injection medroxyprogesterone acetate MPA ( DepoProvera® ) Platelet count le 40,000/mm3 ( Step 1 ) Prothrombin time 5 second great normal range ( Step 1 ) Known hepatitis B , C know HIV positive Patients present Para Kalaazar Dermal Leishmaniasis Signs/symptoms indicative severe VL ( Hb &lt; 5gm/dl , etc ) Patients previous history VL Patients receive investigational ( unlicensed ) drug within last 3 month Severe malnutrition BMI &lt; 15 adult , weight height less 60 % child Clinical symptom chronic underlying disease severe cardiac , renal hepatic impairment Positive HRP2/pLDH Combo test malaria Pregnant woman breastfeed mother Known alcohol drug abuse Concomitant chronic drug treatment eg . TB , HIV etc . Known hypersensitivity AmBisome , Paromomycin aminoglycosides and/or Miltefosine</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>visceral leishmaniasis</keyword>
	<keyword>phase III</keyword>
	<keyword>randomise ccontrolled trial</keyword>
	<keyword>Bangladesh</keyword>
	<keyword>Combination treatment</keyword>
	<keyword>Ambisome</keyword>
	<keyword>miltefosine</keyword>
	<keyword>paromomycin</keyword>
</DOC>